Loading…

Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma

To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically...

Full description

Saved in:
Bibliographic Details
Published in:European journal of radiology 2022-09, Vol.154, p.110415-110415, Article 110415
Main Authors: Wen, Rong, Lin, Peng, Wu, Yuquan, Yin, Haihui, Huang, Weiche, Guo, Danxia, Peng, Yuye, Liu, Dun, He, Yun, Yang, Hong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3
cites cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3
container_end_page 110415
container_issue
container_start_page 110415
container_title European journal of radiology
container_volume 154
creator Wen, Rong
Lin, Peng
Wu, Yuquan
Yin, Haihui
Huang, Weiche
Guo, Danxia
Peng, Yuye
Liu, Dun
He, Yun
Yang, Hong
description To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists. According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60. Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.
doi_str_mv 10.1016/j.ejrad.2022.110415
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2681048776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0720048X22002650</els_id><sourcerecordid>2681048776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EEqXwC1g8sqTYbhK7A0PV8lGpEhKlEptlO-fWIYmLnVTi35MSZqa74X1O9z4I3VIyoYTm9-UEyqCKCSOMTSglKc3O0IgKzhLOGT9HI8IZSUgqPi7RVYwlISRLZ2yEdkundo2PrTP4qKoOsLd48bjd4PUqeZsvN1g1BY4Quhq3Xe0DrlX4hBCx7Xfja-0aKPAeDqr1Bqqqq1RIzN5Xqtk5b1QwrvG1ukYXVlURbv7mGG2fHt8XL8n69Xm1mK8Tw_K8TSxnVAtqdVaYLJ-JKQGiBAjFuNF9Kys0ESrnmhUzbnVBtBHaphnlgmuTwnSM7oa7h-C_OoitrF08_aUa8F2ULBe9HsF53kenQ9QEH2MAKw_B9e2-JSXypFWW8lerPGmVg9aeehgo6FscHQQZjYPGQOECmFYW3v3L_wDMRoKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2681048776</pqid></control><display><type>article</type><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</creator><creatorcontrib>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</creatorcontrib><description>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists. According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60. Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</description><identifier>ISSN: 0720-048X</identifier><identifier>EISSN: 1872-7727</identifier><identifier>DOI: 10.1016/j.ejrad.2022.110415</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Alpha-fetoprotein ; Carbohydrate antigen 199 ; Combined hepatocellular-cholangiocarcinoma ; Contrast-enhanced ultrasound ; Liver Imaging Reporting and Data System</subject><ispartof>European journal of radiology, 2022-09, Vol.154, p.110415-110415, Article 110415</ispartof><rights>2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</citedby><cites>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wen, Rong</creatorcontrib><creatorcontrib>Lin, Peng</creatorcontrib><creatorcontrib>Wu, Yuquan</creatorcontrib><creatorcontrib>Yin, Haihui</creatorcontrib><creatorcontrib>Huang, Weiche</creatorcontrib><creatorcontrib>Guo, Danxia</creatorcontrib><creatorcontrib>Peng, Yuye</creatorcontrib><creatorcontrib>Liu, Dun</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><title>European journal of radiology</title><description>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists. According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60. Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</description><subject>Alpha-fetoprotein</subject><subject>Carbohydrate antigen 199</subject><subject>Combined hepatocellular-cholangiocarcinoma</subject><subject>Contrast-enhanced ultrasound</subject><subject>Liver Imaging Reporting and Data System</subject><issn>0720-048X</issn><issn>1872-7727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EEqXwC1g8sqTYbhK7A0PV8lGpEhKlEptlO-fWIYmLnVTi35MSZqa74X1O9z4I3VIyoYTm9-UEyqCKCSOMTSglKc3O0IgKzhLOGT9HI8IZSUgqPi7RVYwlISRLZ2yEdkundo2PrTP4qKoOsLd48bjd4PUqeZsvN1g1BY4Quhq3Xe0DrlX4hBCx7Xfja-0aKPAeDqr1Bqqqq1RIzN5Xqtk5b1QwrvG1ukYXVlURbv7mGG2fHt8XL8n69Xm1mK8Tw_K8TSxnVAtqdVaYLJ-JKQGiBAjFuNF9Kys0ESrnmhUzbnVBtBHaphnlgmuTwnSM7oa7h-C_OoitrF08_aUa8F2ULBe9HsF53kenQ9QEH2MAKw_B9e2-JSXypFWW8lerPGmVg9aeehgo6FscHQQZjYPGQOECmFYW3v3L_wDMRoKw</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Wen, Rong</creator><creator>Lin, Peng</creator><creator>Wu, Yuquan</creator><creator>Yin, Haihui</creator><creator>Huang, Weiche</creator><creator>Guo, Danxia</creator><creator>Peng, Yuye</creator><creator>Liu, Dun</creator><creator>He, Yun</creator><creator>Yang, Hong</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202209</creationdate><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><author>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alpha-fetoprotein</topic><topic>Carbohydrate antigen 199</topic><topic>Combined hepatocellular-cholangiocarcinoma</topic><topic>Contrast-enhanced ultrasound</topic><topic>Liver Imaging Reporting and Data System</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wen, Rong</creatorcontrib><creatorcontrib>Lin, Peng</creatorcontrib><creatorcontrib>Wu, Yuquan</creatorcontrib><creatorcontrib>Yin, Haihui</creatorcontrib><creatorcontrib>Huang, Weiche</creatorcontrib><creatorcontrib>Guo, Danxia</creatorcontrib><creatorcontrib>Peng, Yuye</creatorcontrib><creatorcontrib>Liu, Dun</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wen, Rong</au><au>Lin, Peng</au><au>Wu, Yuquan</au><au>Yin, Haihui</au><au>Huang, Weiche</au><au>Guo, Danxia</au><au>Peng, Yuye</au><au>Liu, Dun</au><au>He, Yun</au><au>Yang, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</atitle><jtitle>European journal of radiology</jtitle><date>2022-09</date><risdate>2022</risdate><volume>154</volume><spage>110415</spage><epage>110415</epage><pages>110415-110415</pages><artnum>110415</artnum><issn>0720-048X</issn><eissn>1872-7727</eissn><abstract>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists. According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60. Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ejrad.2022.110415</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0720-048X
ispartof European journal of radiology, 2022-09, Vol.154, p.110415-110415, Article 110415
issn 0720-048X
1872-7727
language eng
recordid cdi_proquest_miscellaneous_2681048776
source ScienceDirect Freedom Collection 2022-2024
subjects Alpha-fetoprotein
Carbohydrate antigen 199
Combined hepatocellular-cholangiocarcinoma
Contrast-enhanced ultrasound
Liver Imaging Reporting and Data System
title Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A33%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20value%20of%20CEUS%20LI-RADS%20and%20serum%20tumor%20markers%20for%20combined%20hepatocellular-cholangiocarcinoma&rft.jtitle=European%20journal%20of%20radiology&rft.au=Wen,%20Rong&rft.date=2022-09&rft.volume=154&rft.spage=110415&rft.epage=110415&rft.pages=110415-110415&rft.artnum=110415&rft.issn=0720-048X&rft.eissn=1872-7727&rft_id=info:doi/10.1016/j.ejrad.2022.110415&rft_dat=%3Cproquest_cross%3E2681048776%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2681048776&rft_id=info:pmid/&rfr_iscdi=true